FDA Approval of Axatilimab (Phase 2 AGAVE-201)

home / pivotal-practice-views-with-the-oncology-brothers / fda-approval-of-axatilimab-phase-2-agave-201

Panelists discuss various stages of graft-vs-host disease (GVHD) and chronic GVHD (cGVHD), and the study of axatilimab as a treatment within the AGAVE-201 study.

EP. 1: Overview of Graft-Versus-Host Disease

Rahul Gosain, MD;Rohit Gosain, MD;Shernan Holtan, MD

September 19th 2024

Panelists give an overview of Graft-vs-host Disease and the modern landscape of treatment.

Watch

EP. 2: Overview of Chronic Graft-Versus-Host Disease, and AGAVE-201 Study Design

Rahul Gosain, MD;Rohit Gosain, MD;Shernan Holtan, MD

September 19th 2024

Panelists give an overview of chronic graft-vs-host disease, its history of treatment, how it is handled in the modern day, and the study design of AGAVE-201.

Watch

EP. 3: Results of the AGAVE-201 Study

Rahul Gosain, MD;Rohit Gosain, MD;Shernan Holtan, MD

September 19th 2024

Panelists discuss what the AGAVE-201 study displayed.

Watch

EP. 4: Sequencing Axatilimab and Safety

Rahul Gosain, MD;Rohit Gosain, MD;Shernan Holtan, MD

September 19th 2024

Panelists discuss where and when sequencing axatilimab becomes appropriate within the clinical setting, as well as safety precautions associated with the drug.

Watch